Long-term pioglitazone treatment enhances lipolysis in rat adipose tissue

International Journal of Obesity

Volumn 32, Issue 12, 2008, Pages 1848-1853

  Pravenec, M ^a   Kazdova L ^b   Maxova M ^b   Zidek V ^a   Mlejnek, P ^a   Simakova M ^a   Kurtz, T W ^c  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adipose tissue; Lipolysis; NEFA reesterification; Pioglitazone; Rat

Indexed keywords

ADIPONECTIN; FATTY ACID; INSULIN; MITOCHONDRIAL DNA; PIOGLITAZONE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE METABOLISM; CONGENIC STRAIN; CONTROLLED STUDY; DRUG ACTIVITY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; LIPID METABOLISM; LIPOLYSIS; LONG TERM CARE; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; DNA, MITOCHONDRIAL; FATTY ACIDS, NONESTERIFIED; GLYCEROL; HYPOGLYCEMIC AGENTS; INSULIN; LIPOLYSIS; MUSCLE, SKELETAL; PALMITATES; RATS; RATS, INBRED SHR; THIAZOLIDINEDIONES; TRIGLYCERIDES;

RATTUS;

EID: 57749182685     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2008.192     Document Type: Article

References (22)

1. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50: 1863-1871.
2. Smith SA. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones. Biochimie 2003; 85: 1219-1230.
3. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18 (Suppl 2): S10-S15.
4. Cadoudal T, Leroyer S, Reis AF, Tordjman J, Durant S, Fouque F et al. Proposed involvement of adipocyte glyceroneogenesis and phosphoenolpyruvate carboxykinase in the metabolic syndrome. Biochimie 2005; 87: 27-32.
5. Cadoudal T, Blouin JM, Collinet M, Fouque F, Tan GD, Loizon E et al. Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes. Diabetologia 2007; 50: 666-675.
6. Reshef L, Olswang Y, Cassuto H, Blum B, Croniger CM, Kalhan SC et al. Glyceroneogenesis and the triglyceride/fatty acid cycle. J Biol Chem 2003; 278: 30413-30416.
7. Forest C, Tordjman J, Glorian M, Duplus E, Chauvet G, Quette J et al. Fatty acid recycling in adipocytes: a role for glyceroneogenesis and phosphoenolpyruvate carboxykinase. Biochem Soc Trans 2003; 31 (Part 6): 1125-1129.
8. Glorian M, Duplus E, Beale EG, Scott DK, Granner DK, Forest C. A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. Biochimie 2001; 83: 933-943.
9. Tordjman J, Chauvet G, Quette J, Beale EG, Forest C, Antoine B. Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. J Biol Chem 2003; 278: 18785-18790.
10. Kalderon B, Mayorek N, Ben-Yaacov L, Bar-Tana J. Adipose tissue sensitization to insulin induced by troglitazone and MEDICA 16 in obese Zucker rats in vivo. Am J Physiol Endocrinol Metab 2003; 284: E795-E803.
11. Oakes ND, Thalen PG, Jacinto SM, Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 2001; 50: 1158-1165.
12. Festuccia WT, Laplante M, Berthiaume M, Gélinas Y, Deshaies Y. PPARgamma agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control. Diabetologia 2006; 49: 2427-2436.
13. Pravenec M, Zidek V, Simakova M, Kren V, Krenova D, Horky K et al. Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. J Clin Invest 1999; 103: 1651-1657.
14. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 1999; 21: 76-83.
15. Pravenec M, Landa V, Zidek V, Musilova A, Kren V, Kazdova L et al. Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat Genet 2001; 27: 156-158.
16. Qi N, Kazdova L, Zidek V, Landa V, Kren V, Pershadsingh HA et al. Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone. J Biol Chem 2002; 277: 48501-48507.
17. Cuthbertson WFJ. Nutrients requirements of rats and mice. Proc Nutr Soc 1957; 16: 70-77.
18. Vrána A, Kazdová L. Increased adipose tissue lipolysis in a hypertriglyceridemic rat line. Ann N Y Acad Sci 1997; 827: 510-513.
19. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002; 32: 1372-1379.
20. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Erratum. Biotechniques 2002; 33: 514.
21. Pravenec M, Hyakukoku M, Houstek J, Zidek V, Landa V, Mlejnek P et al. Direct linkage of mitochondrial genome variation to risk factors for type 2 diabetes in conplastic strains. Genome Res 2007; 17: 1319-1326.
22. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acid Res 2002; 30: e36.